Donald A. Bergstrom - Feb 22, 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President, R&D
Signature
/s/ Brian Adams, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Feb 22, 2022
Transactions value $
-$448,617
Form type
4
Date filed
2/22/2022, 08:01 PM
Previous filing
Jan 31, 2022
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $33K +8K +7.28% $4.12 118K Feb 22, 2022 Direct F1, F2
transaction RLAY Common Stock Sale -$168K -8K -6.78% $20.94 110K Feb 22, 2022 Direct F1, F2, F3
transaction RLAY Common Stock Sale -$256K -12.2K -11.14% $20.94 97.7K Feb 22, 2022 Direct F1, F2, F4
transaction RLAY Common Stock Sale -$57.7K -2.75K -2.82% $20.97 94.9K Feb 22, 2022 Direct F1, F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -8K -3.16% $0.00 245K Feb 22, 2022 Common Stock 8K $4.12 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
F2 Includes 93,387 shares underlying restricted stock units.
F3 This transaction was executed in multiple trades at prices ranging from $20.27 to $21.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 This transaction was executed in multiple trades at prices ranging from $20.26 to $21.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 This transaction was executed in multiple trades at prices ranging from $20.76 to $21.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6 Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.